200 related articles for article (PubMed ID: 23372655)
1. Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice.
Hayata K; Iwahashi M; Ojima T; Katsuda M; Iida T; Nakamori M; Ueda K; Nakamura M; Miyazawa M; Tsuji T; Yamaue H
PLoS One; 2013; 8(1):e53131. PubMed ID: 23372655
[TBL] [Abstract][Full Text] [Related]
2. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
3. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
4. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
5. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.
Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB
Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128
[TBL] [Abstract][Full Text] [Related]
6. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis.
Wang Z; Liu JQ; Liu Z; Shen R; Zhang G; Xu J; Basu S; Feng Y; Bai XF
J Immunol; 2013 Mar; 190(5):2415-23. PubMed ID: 23345334
[TBL] [Abstract][Full Text] [Related]
8. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
9. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
Jarnicki AG; Lysaght J; Todryk S; Mills KH
J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
Ahn HM; Hong J; Yun CO
Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
[TBL] [Abstract][Full Text] [Related]
11. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
12. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model.
Pachynski RK; Scholz A; Monnier J; Butcher EC; Zabel BA
J Vis Exp; 2015 Apr; (98):. PubMed ID: 25938949
[TBL] [Abstract][Full Text] [Related]
14. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
Cao X; Wang Q; Ju DW; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
[TBL] [Abstract][Full Text] [Related]
15. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
16. Locally Targeting the IL-17/IL-17RA Axis Reduced Tumor Growth in a Murine B16F10 Melanoma Model.
Chen YS; Huang TH; Liu CL; Chen HS; Lee MH; Chen HW; Shen CR
Hum Gene Ther; 2019 Mar; 30(3):273-285. PubMed ID: 30079767
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
Aznar MA; Planelles L; Perez-Olivares M; Molina C; Garasa S; Etxeberría I; Perez G; Rodriguez I; Bolaños E; Lopez-Casas P; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Teijeira A; Quintero M; Melero I
J Immunother Cancer; 2019 May; 7(1):116. PubMed ID: 31046839
[TBL] [Abstract][Full Text] [Related]
18. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
Front Immunol; 2020; 11():1885. PubMed ID: 33042110
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8
Jevtovic A; Pantic J; Jovanovic I; Milovanovic M; Stanojevic I; Vojvodic D; Arsenijevic N; Lukic ML; Radosavljevic GD
Cancer Immunol Immunother; 2020 Aug; 69(8):1461-1475. PubMed ID: 32285171
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of aquaporin-1 dependent angiogenesis impairs tumour growth in a mouse model of melanoma.
Nicchia GP; Stigliano C; Sparaneo A; Rossi A; Frigeri A; Svelto M
J Mol Med (Berl); 2013 May; 91(5):613-23. PubMed ID: 23197380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
